Results 21 to 30 of about 143,361 (253)

Clostridioides difficile [PDF]

Trends in Microbiology, 2018
Clostridioides difficile is a spore-forming, anaerobic, intestinal pathogen that causes severe diarrhea that can lead to death. In 2011, C. difficile infected ∼500000 people in the USA and killed ∼29000 people. C. difficile infection (CDI) is the most common healthcare-related infection in the USA, leading to increased healthcare costs of $4.8 billion.
Brindar K, Sandhu, Shonna M, McBride
openaire   +2 more sources

Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records

Frontiers in Immunology, 2021
BackgroundClostridioides difficile is a major cause of healthcare-associated and community-acquired diarrhea. Host genetic susceptibility to Clostridioides difficile infection has not been studied on a large-scale.MethodsA total of 1,160 Clostridioides ...
Jiang Li, Yanfei Zhang, Alexandria L. Jilg, Donna M. Wolk, Harshit S. Khara, Amy Kolinovsky, David D. K. Rolston, Raquel Hontecillas, Josep Bassaganya-Riera, Marc S. Williams, Vida Abedi, Ming Ta Michael Lee   +11 more
doaj   +1 more source

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.

Clinical Infectious Diseases, 2021
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI.
Stuart Johnson, V. Lavergne, Andrew M. Skinner, A. Gonzales-Luna, K. Garey, C. Kelly, M. Wilcox   +6 more
semanticscholar   +1 more source

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections

American Journal of Gastroenterology, 2021
Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C.
C. Kelly, M. Fischer, J. Allegretti, K. LaPlante, D. Stewart, B. Limketkai, N. Stollman   +6 more
semanticscholar   +1 more source

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.

New England Journal of Medicine, 2022
BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria.
P. Feuerstadt, T. Louie, B. Lashner, E. Wang, Liyang Diao, J. Bryant, M. Sims, Colleen S Kraft, Stuart H. Cohen, C. Berenson, L. Korman, Christopher B. Ford, Kevin D. Litcofsky, M. Lombardo, J. Wortman, Henry Wu, J. Auniņš, Christopher McChalicher, J. Winkler, B. McGovern, M. Trucksis, M. Henn, L. V. von Moltke   +22 more
semanticscholar   +1 more source

Molecular epidemiology and antimicrobial resistance of Clostridioides difficile detected in chicken, soil and human samples from Zimbabwe

International Journal of Infectious Diseases, 2020
Background: Clostridioides difficile is the major cause of infectious nosocomial diarrhoea in industrialized nations. Data on the occurrence of C. difficile in Africa, ribotype (RT) distribution, antimicrobial susceptibility patterns and potential ...
Fabian K. Berger, Alexander Mellmann, Markus Bischoff, Lutz von Müller, Sören L. Becker, Clifford Simango, Barbara Gärtner   +6 more
doaj   +1 more source

IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy of Clostridioides difficile infection

Gut Microbes, 2021
Clostridioides difficile infection is currently the leading cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis worldwide. Cathelicidins, a major group of natural antimicrobial peptides, have antimicrobial and immunomodulatory
Banglao Xu, Xianan Wu, Yi Gong, Ju Cao
doaj   +1 more source

Epidemiology of Clostridioides difficile Infection in Portugal: A Retrospective, Observational Study of Hospitalized Patients

Acta Médica Portuguesa, 2022
Introduction: Clostridioides difficile is the main cause of healthcare-associated diarrhea in Europe and North America. The aim of this study was to characterize the epidemiology and clinical burden of Clostridioides difficile infection among ...
Cláudia Nazareth, Inês Leitão, Ernestina Reis, Hugo Inácio, Filomena Martins, Elmano Ramalheira, Flávia Cunha, Carla Santos, Sara Lino, Hugo Moreira, Nadiya Kruptsala, Andrea Santos, Laura Paixão, Leonor Pássaro, Mónica Oleastro   +14 more
doaj   +1 more source

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Drugs, 2022
Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is ...
S. Khanna, M. Assi, Christine Lee, David L. Yoho, T. Louie, W. Knapple, H. Aguilar, J. Garcia-Diaz, Gary P. Wang, S. Berry, Joe Marion, Xin Su, Tricia L. Braun, Lindy L. Bancke, P. Feuerstadt   +14 more
semanticscholar   +1 more source

Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

New England Journal of Medicine, 2020
BACKGROUND Efforts to prevent Clostridioides difficile infection continue to expand across the health care spectrum in the United States. Whether these efforts are reducing the national burden of C. difficile infection is unclear.
A. Guh, Yi Mu, L. Winston, Helen L. Johnston, Danyel M. Olson, M. Farley, L. Wilson, S. Holzbauer, Erin C. Phipps, G. Dumyati, Z. Beldavs, M. Kainer, M. Karlsson, D. Gerding, L. McDonald   +14 more
semanticscholar   +1 more source